Italian Diffuse/Multivessel Disease ABSORB Prospective Registry under the auspices of Società Italiana di Cardiologia Invasive-GISE (IT-DISAPPEARS): study design and rationale
J Cardiovasc Med (Hagerstown). 2014 Dec 2. [Epub ahead of print]
22
December
Dec
2014
11 years ago
A growing body of evidence worldwide is supporting implementation of everolimus-eluting bioresorbable vascular scaffold into daily practice as being associated with comparable results as the second-generation everolimus-eluting stent. However, these pieces of evidence come from 'studies in which the majority of the patients had low-risk stenoses', whereas patients with more complex coronary artery disease could benefit the most from the Absorb BVS technology.
The study IT-DISAPPEARS aims to investigate the procedural and clinical performance of the Absorb BVS in patients with long (>24 mm), single-vessel coronary disease or with multivessel disease. At least 50 centers across the Italian territory will enroll 1000 patients with either stable or acute coronary syndromes. Follow-up will end up at 5 years.
The study could provide the first evidence worldwide concerning the performance of Absorb BVS in patients with high-risk diffuse coronary disease.
Go to NCBI abstract
The study IT-DISAPPEARS aims to investigate the procedural and clinical performance of the Absorb BVS in patients with long (>24 mm), single-vessel coronary disease or with multivessel disease. At least 50 centers across the Italian territory will enroll 1000 patients with either stable or acute coronary syndromes. Follow-up will end up at 5 years.
The study could provide the first evidence worldwide concerning the performance of Absorb BVS in patients with high-risk diffuse coronary disease.
Go to NCBI abstract